Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02421172 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT02421172 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 66 participants.
The verdict
NCT02421172, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to placebo. The study has two periods to explore preliminary dose effects.
Interventions
- DRUG Placebo
- BIOLOGICAL CJM112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-04-13 |
| Est. Completion | 2016-11-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02421172
The ClinicalTrials.gov registry entry for NCT02421172 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02421172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02421172 about?
NCT02421172 is a clinical study titled "Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients". This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to placebo. The study has two periods to explore preliminary dose effects.
What is the current status of trial NCT02421172?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2015-04-13. Estimated completion is 2016-11-23.
What interventions are being tested in trial NCT02421172?
The interventions under investigation include: Placebo (DRUG), CJM112 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02421172?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.